Canada Veterinary Ocular Corticosteroids Market Size by Product Type 2024 to 2032

A steady transformation shaped the veterinary ocular corticosteroid landscape in 2024, as the market recorded notable differentiation across product classes. Branded veterinary products dominated the market at USD 1,971.56 thousand, outperforming generics at USD 1,542.13 thousand, while compounded drugs stood at USD 621.86 thousand and off-label human formulations reached USD 413.51 thousand. The leadership of branded products highlighted their reliability and preference among veterinarians for treating ocular disorders. The Canada Veterinary Ocular Corticosteroids Market in 2024 exhibited a strong tilt toward premium and clinically tested formulations, as higher efficacy, consistent clinical outcomes, and strong distribution through veterinary channels drove their dominance.

In 2025, the segment is estimated to maintain its dominance, with branded variants valued at USD 2,010.02 thousand, retaining the top position over generics at USD 1,592.44 thousand, while compounded and off-label drugs remain comparatively lower. From 2026 to 2032, the market is projected to continue scaling, with branded products advancing to USD 2,566.21 thousand and compounded drugs reaching USD 866.42 thousand by 2032. The ongoing dominance of branded formulations in the Canada Veterinary Ophthalmic Corticosteroids Market is expected to be driven by sustained innovation, trusted product performance, and the growing preference for standardised, regulatory-approved treatments that ensure safety and therapeutic precision across diverse animal eye conditions.